Reported Saturday, Genmab Reports Rina-S Showed 45.9% ORR, 9.5-Month mPFS And 12.1-Month mDOR In Platinum-Resistant Ovarian Cancer, With Activity Regardless Of FRα Expression Levels

Genmab reported that its treatment Rina-S, administered at 120 mg/m² every three weeks, achieved a 45.9% objective response rate (ORR) in patients with platinum-resistant ovarian cancer. The treatment also demonstrated a median progression-free survival (mPFS) of 9.5 months and a median duration of response (mDOR) of 12.1 months, with antitumor activity observed regardless of folate receptor alpha (FRα) expression levels.